Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $65 to $95.
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $65 to $95.